CFM
KZR

Catalyst Funds Management’s Kezar Life Sciences KZR Stock Holding History

Catalyst Funds Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,830
Closed -$14.2K – 831
2024
Q3 		$14.2K Hold
1,830
– – ﹤0.01% 1134
2024
Q2 		$11K Buy
+1,830
New +$13.9K ﹤0.01% 893

Other funds holding KZR

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Catalyst Funds Management's KZR Position: Q4 2024 in Review

Catalyst Funds Management sold out of Kezar Life Sciences (KZR) in Q4 2024, closing a stake of 1,830 shares — an estimated $14.2K sold.

Catalyst Funds Management first reported a position in KZR in Q2 2024 and held it in 2 quarters. The position peaked at $14.2K in Q3 2024. 43 funds tracked by Wall St. Rank hold KZR as of Q4 2024.

  • Catalyst Funds Management reported no remaining Kezar Life Sciences position as of Q4 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 1,830 Kezar Life Sciences shares in Q4 2024, an estimated $14.2K.
  • Catalyst Funds Management first reported a position in Kezar Life Sciences in Q2 2024 and held it in 2 quarters.
  • Catalyst Funds Management's Kezar Life Sciences position peaked at $14.2K in Q3 2024.
  • 43 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q4 2024.

Based on Catalyst Funds Management's 13F filing for Q4 2024, filed 10 Feb 2025.